NCT04671303View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

July 27, 2023

Conditions
Lung Cancer
Interventions
DRUG

Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate

"Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week Furmonertinib Mesylate：The dose of Furmonertinib Mesylate is 80 mg once a day, 2 tablets each time, taken orally on an empty stomach before breakfast.~Take medicine continuously for 3 weeks (21 days) for 1 cycle."

Trial Locations (1)

100021

cancer hospital Chinese academy of medical sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER

NCT04671303 - To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer | Biotech Hunter | Biotech Hunter